| Species |
Human |
| Protein Construction |
IL-18 (Tyr37-Asp193)
Accession # Q14116 |
|
| Purity |
> 95% as determined by BisTris PAGE
> 95% as determined by HPLC |
| Endotoxin Level |
Less than 0.1EU per μg by the LAL method. |
| Biological Activity |
Measured by its binding ability in a functional ELISA. Immobilized IL-18, Human at 5μg/ml (100μl/Well) on the plate can bind Human IL18BP, hFc Tag. Test result was comparable to standard batch.
Measured by its ability to induce Interferon gamma secretion by human natural killer lymphoma NK92 cells. The ED50 for this effect is 15 ng/mL. Test result was comparable to standard batch. |
| Expression System |
E.coli |
| Theoretical Molecular Weight |
18.2 kDa |
| Apparent Molecular Weight |
The protein has a predicted MW of 18.2 kDa same as Bis-Tris PAGE result. |
| Formulation |
Lyophilized from 0.22μm filtered solution in 20mM PB, 250mM NaCl, 50mM L-arginine (pH 7.4). |
| Reconstitution |
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. |
| Storage & Stability |
Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |
| Target Background |
Interleukin (IL)-18 was originally discovered as a factor that enhanced IFN-γ production from anti-CD3-stimulated Th1 cells, especially in the presence of IL-12. Upon stimulation with Ag plus IL-12, naïve T cells develop into IL-18 receptor (IL-18R) expressing Th1 cells, which increase IFN-γ production in response to IL-18 stimulation. |
| Synonyms |
IL-18; IL18; IGIF; IL-1F4; IL-1 gamma; IL1F4; IL-1g; Interleukin 1; IL-1γ; IL-1 γ |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
